linjc16/ctgov huggingface dataset:
The Relationship of Phthalate Exposure During Pregnancy and Preeclampsia

Study Overview
=================
Brief Summary
-----------------
Phthalates are a group of ubiquitous synthetic endocrine-disrupting chemicals. Fetal and neonatal periods are particularly susceptible to endocrine disorders, which prenatal exposure to phthalates causes. There is increasing evidence concerning the potential endocrine disrupting for phthalate exposure during pregnancy. Prenatal exposure phthalates would disrupt the level of sex hormone in pregnant women, which results in preeclampsia. The relationship of prenatal phthalate exposure with maternal and neonatal outcomes in human beings was often sex-specific associations. Because of the potentially harmful influence of prenatal phthalate exposure, steps should be taken to prevent or reduce phthalate exposure during pregnancy.

Official Title
-----------------
The Relationship of Phthalate Exposure During Pregnancy and Preeclampsia

Conditions
-----------------
Phthalate Exposure, Preeclampsia, Estrogen, Progestin

Intervention / Treatment
-----------------
* Other: test Phthalates, estrogen and progesterone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton pregnancy Term pregnancy with the gestational age of 37-40 weeks Exclusion Criteria: Maternal systemic diseases (hypertension disorders, immunological diseases) or pregnant complications (polyhydramnios, oligohydramnios, diabetes mellitus, intrahepatic cholestasis of pregnancy) Delivery before 37 weeks or after 40 weeks

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy pregnant woman<br>pregnant woman without any disease of pregnancy | Other: test Phthalates, estrogen and progesterone<br>* test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue<br>|
| pregnant woman with preeclampia<br>pregnant woman with preeclampia but without any other disease of pregnancy | Other: test Phthalates, estrogen and progesterone<br>* test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Phthalates in urine | Collect the urine of pregnant women and test the abundance of Phthalates | 37 weeks to 40 weeks gestation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The female progesterone | Collect the placenta tissue of pregnant women and test the abundance of estrogen progesterone receptor | 37 weeks to 40 weeks gestation |
Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

Study Overview
=================
Brief Summary
-----------------
Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute. The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.

Official Title
-----------------
Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

Conditions
-----------------
Retinoblastoma

Intervention / Treatment
-----------------
* Drug: intra-arterial administration of melphalan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with unilateral/bilateral retinoblastoma Exclusion Criteria: patients with trilateral retinoblastoma extraoculer involvement patients with blood dyscrasias, bleeding and clotting disorders

Ages Eligible for Study
-----------------
Minimum Age: 5 Months
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group 1<br>Patients who received intra-arterial chemotherapy as a first line treatment | Drug: intra-arterial administration of melphalan<br> <br> |
| group 2<br>Patients who received intra-arterial chemotherapy as a salvage treatment after systemic chemotherapy | Drug: intra-arterial administration of melphalan<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| globe salvage | globe salvage rate after superselective intra-arterial chemotherapy treatment for retinoblastoma | 2-5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
enucleation, globe salvage, superselective intra-arterial chemotherapy
Silver Nanoparticles in Multidrug Resistant Bacteria

Study Overview
=================
Brief Summary
-----------------
Recently, silver nanoparticles (AgNPs) have been widely used in various applications as antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery systems for the treatment of various diseases. The present study investigated the bactericidal effect of AgNPs against Methecillin Resistant Staph. aureus (MRSA) and Vancomycin resistant Staph aureus (VRSA)

Official Title
-----------------
Bactericidal Effect of Silver Nanoparticles on Methecillin and Vancomycin Resistant Staphylococcus. Aureus (MRSA) Isolated From Critically Ill Patients

Conditions
-----------------
Multidrug Resistent Bacteria

Intervention / Treatment
-----------------
* Other: silver nanoparticles


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intensive care patients Exclusion Criteria: none
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Methicillin resistant staphylococcus aureus<br> | Other: silver nanoparticles<br>* effect silver nanoparticles will be examined on multidrug resistant bacteria<br>|
| vancomycin resistent staphylococcus aureus<br> | Other: silver nanoparticles<br>* effect silver nanoparticles will be examined on multidrug resistant bacteria<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bactericidal effect of silver nanoparticles on multidrug resistant bacteria |  | 24 hours |
Drug Abuse During the COVID-19 Pandemic.

Study Overview
=================
Brief Summary
-----------------
The pandemic we live through has put various sectors of the medical system and its tributaries to the test. The accumulation of external and internal stress has been completely correlated with the predisposition to psycho-emotional problems and, in turn, to drug use as an immature response for ego protection. That is why the economic, social, and psychological evaluation can help understand the current situation about drug abuse and how to help patients afflicted by it. The added stress of personal problems, work alterations, daily life in a pandemic, economic and varied responsibilities, and the understanding of the pandemic have predisposed and amplified the use of drugs to reduce emotional distress perceived by individuals. The hypothesis of this study is that the increment of stress and a lack of preparation for the pandemic are associated with increased drug abuse.

Official Title
-----------------
Readiness for a Pandemic, and Factors Associated With Substance Abuse During the COVID-19 Pandemic - A Cross-Sectional Study

Conditions
-----------------
Substance Abuse, Stress, Psychological

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 18 years old Willing to participate in the study Patient currently with a paying job Exclusion Criteria: Patients without a paying job

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Behaviour on drug and substance abuse | The survey inquires about the frequency and dosage of numerous substances such as coffee, alcohol, tobacco, and heroin since the pandemic started. | Baseline | 
| PHQ-9 Score | This inventory will be used to identify the presence and intensity of depressive disorders. The minimum score is 0, and the maximum score is 27. | Baseline | 
| GAD-7 Score | This questionnaire will be used to evaluate the presence and intensity of anxiety disorders. The minimum score is 0, and the maximum score is 21. | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
substance abuse, COVID-19, stress, economical impact
Epidemiology of Hypertensive Emergency

Study Overview
=================
Brief Summary
-----------------
To test the hypotheses that hypertensive emergency was associated with non-compliance with antihypertensive medication, low level of contact with the medical care system, and alcohol abuse and cigarette smoking. Also, to describe the clinical characteristics of patients hospitalized with hypertensive emergency including morbidity, mortality, and cost, and the extent to which hypertensive emergency occured among previously diagnosed and treated hypertensives.

Detailed Description
-----------------
BACKGROUND: While less frequent than in the era before effective treatment for hypertension, hypertensive emergency remains a relatively common cause of hospital admission in some sub-populations. In 1989, hypertensive emergency accounted for approximately 60 admissions per year to the Medical Service at Presbyterian Hospital, and a somewhat higher proportion of intensive care unit admissions and utilization. The importance of hypertensive emergency may have been underestimated because the International Classification of Diseases discharge codes included only malignant hypertension, a severe form comprising only about half of the admissions for hypertensive emergency. There had been almost no epidemiologic studies of hypertensive emergency since 1969, and very little was known about risk factors. DESIGN NARRATIVE: A matched case-control study design was used. Cases were obtained from admissions to the Medical Service at Presbyterian Hospital. Morbidity and mortality data were obtained by follow-up of the case series.

Official Title
-----------------
Correlates of Nonadherence to Hypertension Treatment in an Inner-City Minority Population

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria 1. Patients admitted in the emergency room and for the medical and surgical services at the Presbyterian Hospital and Harlem Hospital Center in New York City patients with incidents of hypertensive emergency or hypertensive urgency hypertensive patients with other acute conditions who were admitted to the hospital or were treated in the emergency room and released Exclusion criteria Under 21 years of age Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Pediatric Telephone Center Board 15

Study Overview
=================
Brief Summary
-----------------
This study evaluates the follow-up of advices given in a Urgent Medical Aid Service (SAMU 29) for every pediatric's emergency call under 15yo and try to evaluate the adhesion's factors.

Detailed Description
-----------------
Many of pediatric's medical emergency are followed by a medical advice in a Urgent Medical aid Service (SAMU). This advices could be medications advices, to see a general praticionner the same day or later, or to consult in an emergency department. But the rate of advices really followed by callers is unknown. This study evaluate by who, when and why this advices are followed or not.

Official Title
-----------------
Pediatric Telephone Center Board 15 and Adhesion Factors

Conditions
-----------------
Emergencies, Pediatric ALL, Response, Acute Phase

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all emergency calls at SAMU 29 for under 15yo childs medical advices were given by the physician (medication at home OR consult in an emergency department OR consult the general praticionner the same day or later. Exclusion Criteria: all emergency calls at SAMU 29 for upper 15yo childs participation opposition. need for an ambulance or an emergency medical team at home

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of medical advices with follow-up completed in epidemic condition | number of medical advices followed after calling SAMU in epidemic condition | 10 days | 
| rate of medical advices with follow-up completed in summer | number of medical advices followed after calling SAMU in summer | 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| epidemiology of pediatric's emergency calls in Urgent Medical Aid Service (SAMU 29) | Who, when and why population calls for an pediatric's emergency probleme | 10 days in epidemic condition | 
| epidemiology of pediatric's emergency calls in Urgent Medical Aid Service (SAMU 29) | Who, when and why population calls for an pediatric's emergency probleme | 10 days in summer | 
| adhesion factors to follow medical advice | By who, when and why medical advices were not followed by callers | 10 days in epidemic condition | 
| adhesion factors to follow medical advice | By who, when and why medical advices were not followed by callers | 10 days in summer | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Urgent Medical Aid Service (SAMU), Pediatric
Aortic Dissection With 4-dimensional Phase-contrast Magnetic Resonance Imaging

Study Overview
=================
Brief Summary
-----------------
We prospectively collected information on consecutive patients who had been evaluated using 4D PC-MRI for aortic pathology in a tertiary hospital between April 2018 and Feb 2020. Patients were eligible for inclusion in the study if they had a clinical indication for CTA of aortic dissections.

Detailed Description
-----------------
The exclusion criteria were non-MRI-compatible ferromagnetic devices and pregnancy. In addition, patients with poor compliance and with unstable status that prevented them from lying down for the MRI protocol were excluded. Initially, 26 patients evaluated. One patient was excluded due to fever at the scheduled time, and another was unable to lie down due to complicated spine disease. All patients underwent CTA scan on a 64-slice multidetector scanner (Somatom Sensation 64; Siemens Healthcare, Erlangen, Germany) with the intravenous administration of contrast media, followed by 4D PC-MRI to assess aortic pathology

Official Title
-----------------
Aortic Dissection With 4-dimensional Phase-contrast Magnetic Resonance Imaging

Conditions
-----------------
MRI

Intervention / Treatment
-----------------
* Diagnostic Test: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients were eligible for inclusion in the study if they had a clinical indication for CTA of aortic dissections. The exclusion criteria were non-MRI-compatible ferromagnetic devices and pregnancy. In addition, patients with poor compliance and with unstable status that prevented them from lying down for the MRI protocol were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: MRI|check MRI quality in aorta|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| stroke volume | anatomic/hemodynamic parameter | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse event | diagnostic function | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CVS MRI
Audio Data Collection for Identification and Classification of Coughing

Study Overview
=================
Brief Summary
-----------------
An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.

Official Title
-----------------
Audio Data Collection for Identification and Classification of Coughing

Conditions
-----------------
COVID-19, Coronavirus Infections, Hay Fever, Asthma, Chronic Obstructive Pulmonary Disease, Influenza, Common Cold, Respiratory Tract Infections, Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cohort 1, 3, 4 and 5: Females and males over 18 years old Willing to share demographic data with the sponsor of the study Willing to follow app use instructions during the course of the study Willing to complete survey instruments as described in study procedures Willing to provide electronic informed consent Able to read and understand the English language well enough to complete electronic informed consent Cohort 2: Any person present in the vicinity of a HealthMode Cough Monitoring Device Exclusion Criteria: No exclusion criteria -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort 1<br>Individual Application Downloaders | |
| Cohort 2<br>Public Space and Vehicle Data Capture | |
| Cohort 3<br>Individuals dialing a voice-recording study phone number | |
| Cohort 4<br>Individuals utilizing study website's audio recording functionality | |
| Cohort 5<br>Individuals participating in Return-to-Work Project | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dataset size | Size of collected audio dataset measured as number of collected cough sounds, targeting ≥10,000 identified coughs. | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cough sound identification | Identification of cough sounds by the existing mathematical model with ≥ 99% specificity and ≥ 60% sensitivity | 14 days | 
| Improvement of the existing model | Increase in the sensitivity of the mathematical model to cough sounds to ≥ 70% while retaining the specificity of ≥ 99% | 14 days | 
| Evaluate the usability of the application | Determination of the level of acceptance and satisfaction of the solution by patients by means of a Standard Usability Questionnaire to provide feedback. The score ranges from 10 to 50, higher score indicating a better usability. | 14 days |
PUFA Augmentation in Treatment of Major Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.

Detailed Description
-----------------
As per brief summary

Official Title
-----------------
PUFA Augmentation in Treatment of Major Depression

Conditions
-----------------
Major Depression

Intervention / Treatment
-----------------
* Drug: Polyunsaturated Fatty Acids (PUFA)
* Drug: Citalopram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet DSM-IV criteria for current major depression, and have a HAM-D (21 item) score of > 17 Male or female who, if of child-bearing potential, agrees to use effective contraception including the regular use of contraceptive pills, intra-uterine devices, barrier methods or abstinence Age between 18 and 65 Capable of giving informed consent Exclusion Criteria: Diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression or bipolar disorders Current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous 6 months Unstable medical or neurological conditions that are likely to interfere with the treatment of depression History of allergy to citalopram or ProEPA, finfish or shellfish History of failure of response to citalopram, as documented by an adequate trial of the medication [defined as having been treated with the medication at a dose level typically regarded as adequate (i.e., 40 mg of citalopram per day) for at least 6 weeks] History of seizure disorder Pregnancy Currently on psychotropic medications including antidepressants or neuroleptics Active suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study Exposure to treatment with fluoxetine or MAOIs in the previous two months Patients on anticoagulant therapy Patients with a dietary intake of > 3.0g total omega-3 PUFA/day at baseline

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Polyunsaturated Fatty Acids (PUFA)|nan|
|Drug: Citalopram|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
depression, citalopram, Celexa, Polyunsaturated Fatty Acids, omega-3, EPA, antidepressants